Sign in
Taking people in United StatesPhase 2

DaxibotulinumtoxinA injections for blepharospasm, a condition causing eyelid spasms

Tests daxibotulinumtoxinA injections in adults with blepharospasm, looking at how long they work.

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
DaxibotulinumtoxinA for Blepharospasm
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
24 Sept 2026
Expected to end
31 Dec 2028
Type of study
Interventional
Treatments tested
  • Botulinum Neurotoxin Type A
Record updated
29 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with blepharospasm (uncontrolled blinking or eyelid spasms) who now get onabotulinumtoxinA or incobotulinumtoxinA injections. Their current injections must wear off too soon.

Age
18 years or older
Sex
All sexes can join
Disease stage
Blepharospasm that disrupts life enough to need ongoing botulinum toxin injections, with a score of ≥2 on the BSRS at screening. It may be focal (benign essential), linked to a non-drug cause such as parkinsonism, or part of dystonia of the upper head, if the eyelids are the only area needing injections.
Earlier treatment
Must currently receive onabotulinumtoxinA or incobotulinumtoxinA. The benefit of the last injection lasted <12 weeks. The neurologist judges that the dose cannot be raised further because of side effect risk, such as droopy eyelid or double vision.

Main reasons for not taking part

  • Blepharospasm caused by medicines, or psychogenic/functional blepharospasm
  • Never responding or no longer responding to BoNT-A injections, including known neutralizing antibodies
  • Nerve-muscle or motor neuron disorders such as myasthenia gravis or ALS
  • Pregnant or breastfeeding, planning pregnancy in the next 15 months, or unwilling to use contraception
  • Active eye disease, skin infection at injection sites, or signs of active suicidal thoughts

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Adults (18 years of age, or older)
  • Clinical diagnosis of Blepharospasm that is disruptive enough to warrant ongoing clinical botulinum toxin injections and scoring ≥2 on the BSRS during screening. Blepharospasm may be focal (i.e. Benign essential blepharospasm), associated with non-drug-induced secondary cause (e.g., typical or atypical parkinsonism) or as part of a diagnosis of segmental or generalized dystonia involving the upper cranial region, if blepharospasm is the only indication requiring botulinum toxin injections
  • Currently receiving onabotulinumtoxinA or incobotulinumtoxinA for the treatment of blepharospasm with: 1) documented duration of benefit <12 weeks from most recent injection; and 2) no further dose escalation possible or advised due to side effect risk (e.g., ptosis, diplopia, etc.), as determined by treating neurologist; and 3) ability to provide informed consent and comply with study procedures, or subject has a reliable caregiver/proxy
  • Written informed consent including authorization to release health information

Who cannot take part

  • Tardive or medication-induced blepharospasm, as well as psychogenic/functional blepharospasm
  • Subjects who have undergone Deep Brain Stimulation (DBS) surgery for the management of blepharospasm and are not willing to keep the DBS settings unchanged for the duration of the trial
  • Subjects on oral medications for dystonia (e.g., anticholinergics, muscle relaxants, benzodiazepines, dopamine depleter) who have not been stable on their regimen for at least 4 weeks prior to Screening, or who are not willing to keep them stable for the duration of the trial
  • History of severe (stage 3) chronic obstructive pulmonary disease, or unstable pulmonary disease within 30 days prior to Screening
  • Subjects in an investigational drug or device study within the last 30 days prior to Screening
  • Neuromuscular junction or motor neuron disorders (e.g., myasthenia gravis, Lambert-Eaton Myasthenic Syndrome, Amyotrophic Lateral Sclerosis, etc.)
  • Known hypersensitivity to botulinum toxin or formulation components
  • History of primary or secondary non-response to BoNT-A injections, particularly those known to have neutralizing antibodies to BoNT-A
  • History of chronic or recurrent hypokalemia
  • Active skin infections at the injection sites which would put the subject at increased risk of morbidity with BoNT injections
  • History of blood coagulation disorder that makes facial injection an absolute contraindication
  • Any acute illnesses or medical conditions including cognitive impairment (e.g., dementia), significant psychiatric illnesses (e.g., major depressive or bipolar disorder) or symptoms (e.g., suicidal ideation, psychosis) that are not stable, and in the Investigator's opinion, could put the subject at increased risk of morbidity, confound the study results, or interfere significantly with the subject's participation in the study
  • Use of aminoglycoside antibiotics, polymyxins, lincosamides (e.g., clindamycin), or other agents that might interfere with neuromuscular transmission (e.g., curare-like drugs, quinidine, magnesium sulfate, anticholinesterases, succinylcholine chloride) within 14 days prior to Screening
  • History of congestive heart failure (New York Heart Association Class III or IV), Torsade de Pointe (TdP), and/or Long QT Syndrome
  • Active ocular pathology interfering with evaluation or injection safety
  • Pregnant or breastfeeding women (including those who are found to be pregnant after a positive pregnancy test at Screening), women who are hoping to get pregnant over the upcoming 15 months, or women of childbearing potential who are unwilling to use contraception while enrolled in the BLEXI study
  • Any signal suggestive of active suicidality, as per C-SSRS at screening

Where in United States

  • Parkinson Disease and Movement Disorders Center at the University of PennsylvaniaPhiladelphia, United StatesContact: Alexandria OliverTaking people

About the trial

What the trial wants to find out

This study aims to provide real-world information about the duration, safety, and overall benefit of DaxibotulinumtoxinA (also called DAXI) treatment for adults living with blepharospasm (BSP), a condition that causes uncontrolled blinking or muscle spasms around the eyes, which can interfere with vision and daily activities. Specifically, it is being done to learn more about how well and how long DAXI works for treating adults with blepharospasm.

Read full original descriptionShow less

This is a single-center, open-label, single-arm study, meaning everyone in the study will receive DAXI, and both participants and researchers will know what treatment is being given. The study will include 20 adult participants.

Participants may receive two to three treatment cycles of DAXI injections over about 12 months. The timing between treatments will depend on how long each injection works for each person. Injections will be given at least every 90 days (3 months) but no later than every 180 days (6 months). Participants and their doctors will decide when another injection is needed based on symptom control using a tool called the Blepharospasm Severity Tracker Form (BSTF). To make the injections more comfortable, participants may use topical lidocaine cream, cooling spray, or another local anesthetic before injection.

DAXI will be prepared by the injecting clinician or trained staff right before use. The medication is made by mixing a measured amount of DAXI powder with a small amount of sterile saline solution (salt water) to reach the correct concentration. The exact injection technique (including the dose, location, and number of injection sites) will be chosen by the injector based on each participant's needs, but treatment will only be given in specific facial muscles (corrugator, procerus, orbicularis oculi, and nasalis). The use of imaging tools such as electromyography (EMG) or ultrasound is optional and typically not required for injections around the eyes.

The starting DAXI dose will be based on each participant's current or previous botulinum toxin treatment:

* If the participant was previously treated with onabotulinumtoxinA (Botox®), the same number of "units" will be used for DAXI (a 1:1 conversion). * If the participant was previously treated with incobotulinumtoxinA (Xeomin®), the DAXI dose will be adjusted to about two-thirds of the previous incobotulinumtoxinA dose (a 1.5:1 conversion).

If a participant experienced side effects such as droopy eyelids (ptosis), double vision (diplopia), or dry eyes with prior treatments, that information will help guide dosing decisions. For later injection cycles, the injector may adjust the dose or injection pattern based on how well the participant responds. Whenever possible, the same injector will perform all of a participant's treatments to keep results consistent.

Participants will come to the clinic for in-person visits for most study assessments. After each DAXI injection, the peak effect (best response) will be evaluated about one month later, guided by the BSTF. These visits may be done remotely (via phone or video) when appropriate. The same schedule will be followed for future cycles. For the final treatment, this one-month check will occur unless the participant reports that the treatment's full effect happened sooner.

The main goal (primary endpoint) of the study is to measure how long DAXI's effects last, specifically by tracking the median time until the next injection is needed.

Other key goals (secondary endpoints) include:

* How long participants feel the treatment works * How severe their blepharospasm symptoms are over time * What side effects or safety concerns occur (adverse events)

The group in the trial

  • Open label armTreatment being tested

    The study cohort will consist of adults with blepharospasm who previously received onabotulinumtoxinA or incobotulinumtoxinA and will transition to DAXI 12 weeks after their last botulinum toxin treatment. Each participant will receive a DAXI dose equivalent to their prior therapy, using a 1:1 conversion for onabotulinumtoxinA or a 1.5:1 conversion for incobotulinumtoxinA, adjusted if prior treatment caused excessive weakness or other side effects. Injections will be limited to muscles directly involved in blepharospasm (the orbicularis oculi, corrugators, procerus, and nasalis) and will use a dilution of 10 units per 0.1 mL. Subjects may use topical anesthetics to reduce injection pain, and efforts will ensure the same injector administers all treatments to maintain consistency.

    Treatment: Botulinum Neurotoxin Type A

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
BLEXI: A Study of BLEpharospasm Management With daXIbotulinumtoxinA
Plain-language title
DaxibotulinumtoxinA injections for blepharospasm, a condition causing eyelid spasmsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 September 2026